Quick Answer
Anebulo Pharmaceuticals, Inc. reported Operating Income of -$9.22 million for fiscal year 2025.
Anebulo Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$9.22M | -11.0% |
| 2024 | -$8.31M | +29.5% |
| 2023 | -$11.78M | -72.5% |
| 2022 | -$6.83M | -89.0% |
| 2021 | -$3.61M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.62M | -1.2% | -15.9% |
| September 30, 2025 | -$2.26M | +6.3% | -19.4% |
| March 31, 2025 | -$1.89M | -13.7% | +26.9% |
| December 31, 2024 | -$2.59M | +6.2% | -7.3% |
| September 30, 2024 | -$2.41M | +5.2% | -44.9% |
| March 31, 2024 | -$1.66M | +41.9% | +39.7% |
| December 31, 2023 | -$2.76M | +27.6% | -8.5% |
| September 30, 2023 | -$2.54M | +2.6% | +11.2% |
- Anebulo Pharmaceuticals, Inc. showed a decrease of -11.0% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Anebulo Pharmaceuticals, Inc.’s operating income has declined by 155.2% (from -$3.61 million to -$9.22 million).
- The most recent figure is from Anebulo Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: